Creative Medical Technology (CELZ) Projected to Post Earnings on Friday

Posted by Defense World Staff on Nov 7th, 2025

Creative Medical Technology (NASDAQ:CELZ – Get Free Report) is projected to issue its results before the market opens on Friday, November 14th. Analysts expect the company to announce earnings of ($0.63) per share for the quarter.

Creative Medical Technology (NASDAQ:CELZ – Get Free Report) last announced its quarterly earnings data on Friday, August 8th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.15. On average, analysts expect Creative Medical Technology to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Creative Medical Technology Price Performance

Shares of CELZ opened at $2.97 on Friday. Creative Medical Technology has a 1 year low of $1.69 and a 1 year high of $6.90. The stock’s fifty day moving average price is $3.51 and its two-hundred day moving average price is $2.87. The firm has a market cap of $7.66 million, a PE ratio of -0.93 and a beta of 2.05.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on CELZ shares. Zacks Research upgraded shares of Creative Medical Technology to a “hold” rating in a research note on Tuesday, August 12th. Wall Street Zen raised shares of Creative Medical Technology to a “sell” rating in a report on Saturday, August 9th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Creative Medical Technology in a report on Tuesday, October 14th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce”.

Read Our Latest Analysis on CELZ

Creative Medical Technology Company Profile

(Get Free Report)

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.